Search Results - "Finkelmeier, F."

EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance by Depner, C., zum Buttel, H., Böğürcü, N., Cuesta, A. M., Aburto, M. R., Seidel, S., Finkelmeier, F., Foss, F., Hofmann, J., Kaulich, K., Barbus, S., Segarra, M., Reifenberger, G., Garvalov, B. K., Acker, T., Acker-Palmer, A.

“…Diffuse invasion of the surrounding brain parenchyma is a major obstacle in the treatment of gliomas with various therapeutics, including anti-angiogenic…”
Get full text

Severe 25‐hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma – a prospective cohort study by Finkelmeier, F., Kronenberger, B., Köberle, V., Bojunga, J., Zeuzem, S., Trojan, J., Piiper, A., Waidmann, O.

“…Summary Background Vitamin D is involved in many biological processes. The role of vitamin D in patients with hepatocellular carcinoma (HCC) remains…”
Get full text

Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg‐negative chronic HBV infection by Kuhnhenn, L., Jiang, B., Kubesch, A., Vermehren, J., Knop, V., Susser, S., Dietz, J., Carra, G., Finkelmeier, F., Grammatikos, G., Zeuzem, S., Sarrazin, C., Hildt, E., Peiffer, K.‐H.

“…Summary Background HBV DNA and quantitative (q)HBsAg levels as prognostic markers for HBV‐related disease are mostly validated in Asia and their significance…”
Get full text

Thoracic impedance pneumography in propofol-sedated patients undergoing percutaneous endoscopic gastrostomy (PEG) placement in gastrointestinal endoscopy: A prospective, randomized trial by Michael, F A, Hessz, D, Graf, C, Zimmer, C, Nour, S, Jung, M, Kloka, J, Knabe, M, Welsch, C, Blumenstein, I, Dultz, G, Finkelmeier, F, Walter, D, Mihm, U, Lingwal, N, Zeuzem, S, Bojunga, J, Friedrich-Rust, M

“…To assess the efficacy of an ECG-based method called thoracic impedance pneumography to reduce hypoxic events in endoscopy. This was a single center, 1:1…”
Get full text

P0194 : Severe 25-hydroxyvitamin D deficiency is associated with infections and mortality in cirrhosis by Finkelmeier, F, Kronenberger, B, Zeuzem, S, Piiper, A, Waidmann, O

Get full text

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort by Pomej, K., Balcar, L., Shmanko, K., Welland, S., Himmelsbach, V., Scheiner, B., Mahyera, A., Mozayani, B., Trauner, M., Finkelmeier, F., Weinmann, A., Vogel, A., Pinter, M.

“…There is no clear consensus on the optimal systemic treatment regimen in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) patients. We describe clinical…”
Get full text

Commentary: vitamin D deficiency and liver cancer – cause, effect or myth? Authors’ reply by Finkelmeier, F., Kronenberger, B., Köberle, V., Bojunga, J., Zeuzem, S., Trojan, J., Piiper, A., Waidmann, O.

Get full text

P545 SEVERE 25-HYDROXYVITAMIN D DEFICIENCY IDENTIFIES HCC PATIENTS WITH A POOR PROGNOSIS by Finkelmeier, F, Köberle, V, Kronenberger, B, Bojunga, J, Zeuzem, S, Trojan, J, Piiper, A, Waidmann, O

Get full text

Identifying indications for percutaneous (PTC) vs. endoscopic ultrasound (EUS)- guided "rendezvous" procedure in biliary obstruction and incomplete endoscopic retrograde cholangiography (ERC) by Albert, J G, Finkelmeier, F, Friedrich-Rust, M, Kronenberger, B, Trojan, J, Zeuzem, S, Sarrazin, C

“…The variety of rendezvous (RV) procedures has recently been extended by EUS- and PTCD-guided procedures as a complementary means to conventional ERCP. We have…”
Get more information

Endoscopic findings in patients with eosinophilic esophagitis by Waidmann, O, Finkelmeier, F, Welker, M W, Sprinzl, K, Zeuzem, S, Albert, J G

“…Endoscopy has a key role in establishing the diagnosis of eosinophilic esophagitis (EoE), but endoscopic features of EoE might not be well known. All patients…”
Get more information

154P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB) by Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Iavarone, M.A., Cabibbo, G., Foschi, F.G., Piscaglia, F., Cascinu, S., Scartozzi, M., Casadei Gardini, A.

Get full text

170P Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population by Vitiello, F., Rimini, M., Persano, M., Suda, G., Shimose, S., Finkelmeier, F., Masi, G., Rossari, F., Amadeo, E., Casadei Gardini, A., Tada, T., Kudo, M., Cheon, J., Lim, H.Y., Yoo, C.

Get full text

185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study by Rossari, F., Tada, T., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Amadeo, E., Vitiello, F., Foti, S., Persano, M., Piscaglia, F., Scartozzi, M., Cascinu, S., Rimini, M., Casadei Gardini, A.

Get full text

188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab by Rimini, M., Amadeo, E., Vitiello, F., Foti, S., Persano, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H.Y., Piscaglia, F., Masi, G., Yoo, C., Lonardi, S., Rossari, F., Camera, S., Casadei Gardini, A., Presa, J.

Get full text

173P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB) by Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Iavarone, M.A., Cabibbo, G., Foschi, F.G., Piscaglia, F., Cascinu, S., Scartozzi, M., Casadei Gardini, A.

Get full text

972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma by Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Presa, J., Masi, G., Yoo, C., Lonardi, S., Piscaglia, F., iavarone, M.A., TAMBURINI, E., Cabibbo, G., Silletta, M., Cascinu, S., Scartozzi, M., Casadei Gardini, A.

Get full text

PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments by Persano, M., Rimini, M., Toshifumi, T., Suda, G., Shigeo, S., Kudo, M., Cheon, J., Finkelmeier, F., Presa, J., Masi, G., Yoo, C., Lonardi, S., Tovoli, F., Piscaglia, F., Iavarone, M., Marra, F., Tamburini, E., Cabibbo, G., Scartozzi, M., Casadei-Gardini, A.

Get full text

84P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population by Rimini, M., Casadei-Gardini, A., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H.Y., Rimassa, L., Presa, J., Masi, G., Yoo, C., Lonardi, S., Tovoli, F., Cascinu, S., Cucchetti, A.

Get full text

Thoracic impedance pneumography in propofol-sedated patients undergoing percutaneous endoscopic gastrostomy (PEG) placement in gastrointestinal endoscopy: A prospective, randomized trial 1 1 The results of the present trial were presented at the German national gastroenterology congress in Hamburg in September 2022 and at the German national endoscopy congress in Cologne in March 2023 by Michael, F A, Hessz, D, Graf, C, Zimmer, C, Nour, S, Jung, M, Kloka, J, Knabe, M, Welsch, C, Blumenstein, I, Dultz, G, Finkelmeier, F, Walter, D, Mihm, U, Lingwal, N, Zeuzem, S, Bojunga, J, Friedrich-Rust, M

“…SummaryStudy objectiveTo assess the efficacy of an ECG-based method called thoracic impedance pneumography to reduce hypoxic events in endoscopy.DesignThis was…”
Get full text

Thoracic impedance pneumography in propofol-sedated patients undergoing percutaneous endoscopic gastrostomy (PEG) placement in gastrointestinal endoscopy: A prospective, randomized trial11The results of the present trial were presented at the German national gastroenterology congress in Hamburg in September 2022 and at the German national endoscopy congress in Cologne in March 2023 by Michael, F.A., Hessz, D., Graf, C., Zimmer, C., Nour, S., Jung, M., Kloka, J., Knabe, M., Welsch, C., Blumenstein, I., Dultz, G., Finkelmeier, F., Walter, D., Mihm, U., Lingwal, N., Zeuzem, S., Bojunga, J., Friedrich-Rust, M.

“…To assess the efficacy of an ECG-based method called thoracic impedance pneumography to reduce hypoxic events in endoscopy. This was a single center, 1:1…”
Get full text